October 2015

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg.

Plague has been endemic in the human population since the beginning of the Bronze Age, more than 5,000 years ago, new research has found.

A substance originally found in bananas and carefully edited by scientists could lead to drugs that fight off a wide range of viruses, including those that cause AIDS, Hepatitis C and influenza, new research suggests.

With identification of a biomarker, researchers have found that a single blood test could reveal whether an apparently healthy person is likely to die of pneumonia or sepsis within the next 14 years.

UN agencies on Thursday declared an end to the 2013-2014 polio outbreak in Somalia, which affected nearly 200 people, most of them children.

Treating high blood pressure with antihypertensive medication can greatly reduce your risk for heart attack, stroke and heart failure, but such treatment cannot undo all of the previous damage or restore cardiovascular disease risk to ideal levels, says a study.

Scientists at the Georgia Institute of Technology, Atlanta suggest that humans may be able to regrow their own teeth in the same way as a cichlid fish in Malawi lake. The study was published in the journal Proceedings of the National Academy of Sciences.

Novartis acquire Admune, a clinical-stage biotech company focused on the development and delivery of cytokine therapy drugs for cancer, for the company’s IL-15 agonist program, currently in Phase I clinical trials for metastatic cancer. The fee is not being disclosed. Novartis also signed a $15 million licensing agreement with Palobiofarma. The company, based at Barcelona’s science park, focuses on the discovery and development of new drugs based on the modulation of adenosine receptors.